C
Chengdu Wiskin Biomedical Technology
Developing mRNA therapeutics and cancer vaccines
About Chengdu Wiskin Biomedical Technology
Chengdu Wiskin Biomedical Technology Co., Ltd., also known as WestGene Biopharma, is a biopharmaceutical company established in July 2021. It was co-founded by Dr. Wei Yuquan, an academician of the Chinese Academy of Sciences, and Dr. Xiangrong Song, a scientist with over a decade of experience in mRNA drug research and development who also serves as the CEO. The company is focused on the research and development of innovative mRNA drugs and vaccines.
WestGene's primary work involves developing a pipeline of over 20 mRNA therapeutic products targeting a range of diseases, including cancer, infectious diseases, obesity, and aging. A key product is WGc-043, an mRNA therapeutic cancer vaccine designed to target Epstein-Barr Virus (EBV)-related cancers. In 2024, WGc-043 received Investigational New Drug (IND) approvals from both the U.S. FDA and China's National Medical Products Administration (NMPA), marking a significant milestone for the company. The vaccine works by stimulating the patient's immune system to produce T-cells and antibodies to fight cancer cells and has shown promising safety and efficacy in investigator-initiated trials for nasopharyngeal carcinoma and NK/T-cell lymphoma.
The company's business model appears to be centered on the research, development, and future commercialization of its drug pipeline. WestGene is open to various forms of commercial collaboration, including pipeline licensing, co-development, and technology licensing. WestGene has secured significant funding, including a Series A round of $41.8 million in 2023, to support clinical trials and further research. The company has established five key R&D platforms, including platforms for cancer therapy vaccines, protein replacement drugs, gene editing technology, and preventive vaccines, and has developed a patented LNP delivery system for its mRNA products.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2023 | $21M | $84M | Tigermed · Hangzhou Tigermed · Chengdu Guanghua Wutong Equity Investment · Konruns Pharmaceutical | ↗ |
| SERIES A✓Equity / VC | Dec 2022 | $21M | $83M | Undisclosed | — |
Growth signals
Latest recorded traffic for Chengdu Wiskin Biomedical Technology is 350 monthly website visits, up 288.9% over the last three months. Chengdu Wiskin Biomedical Technology's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Wiskin Biomedical Technology in its local ecosystem
The Chengdu Wiskin Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Tigermed
Hangzhou Tigermed- CIChengdu Guanghua Wutong Equity Investment
- KPKonruns Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chengdu Wiskin Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chengdu Wiskin Biomedical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










